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Abstract
Patients with refractory chronic migraine have substantial disability and have failed many
acute and preventive medications. When aggressive intravenous therapy is indicated, both
lidocaine and (R,S)-ketamine infusions have been used successfully to provide relief.
Retrospective studies have shown that both agents may be associated with short-term analgesia.
In this prospective, observational pilot study of 6 patients we compared the effects of lidocaine
and (R,S)-ketamine infusions and performed metabolite analyses of (R,S)-ketamine to determine
its metabolic profile in this population. One of (R,S)-ketamine’s metabolites, (2R,6R)hydroxynorketamine, has been shown in animal studies to reduce pain but human studies in
patients undergoing continuous (R,S)-ketamine infusions for migraine are lacking. All 6 patients
tolerated both infusions well with mild adverse effects. The baseline mean pain rating (0-10
numeric rating scale) decreased from 7.5 ± 2.2 to 4.7 ± 2.8 by end of lidocaine treatment
(p≤0.05) but increased to 7.0 ± 1.4 by the post-discharge visit at 4 weeks (p>0.05 versus
baseline). The baseline mean pain rating prior to ketamine treatment was 7.4 ± 1.4, which
decreased to 3.7 ± 2.3 by the end of the hospitalization (p≤0.05), but increased to 7.2 ± 1.7 by
the post-discharge visit at 6 weeks (p>0.05 versus baseline). For the primary outcome the change
in pain from baseline to end of treatment was greater for ketamine than lidocaine (-3.7 versus 2.8, p≤0.05) but this has minimal clinical significance. Ketamine metabolite analysis revealed
that (2R,6R)-hydroxynorketamine was the predominant metabolite during most of the infusion,
consistent with previous studies.
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Introduction
Patients with refractory chronic migraine often have continuous pain and non-painful
symptoms, substantial disability, and have failed multiple medications.1 The degree of
intractability in refractory chronic migraine has been characterized based on response to
preventive treatments, progressing from mild (class 1) to very severe (class 4).2 Patients in class
4 have often failed typical inpatient or outpatient infusion treatment and are left with few if any
options. One medication that has shown promise in retrospective studies is (R,S)-ketamine.3 A 5day continuous infusion of (R,S)-ketamine was associated with short-term improvement with
manageable adverse effects in more than 75% of patients in one study.4 Of those who were shortterm responders, 30-40% reported sustained response at 1 and 3 months.
(R,S)-ketamine is rapidly and extensively metabolized by cytochrome P450 enzymes
(CYPs) into multiple metabolites, including a key metabolite (2R,6R;2S,6S)hydroxynorketamine (HNK).5 Both (2R,6R)- and (2S,6S)-HNK enantiomers have been shown to
produce anti-depressant responses in mouse models of depression.6 Recent studies in murine
models of neuropathic pain demonstrated that (2R,6R)-HNK possesses intrinsic analgesic
properties,7 appears to be more potent than (R,S)-ketamine.5 (2R,6R;2S,6S)-HNK was also the
major circulating metabolite in a plasma sample from a patient receiving a continuous 5-day
infusion of (R,S)-ketamine for the treatment of complex regional pain syndrome.8 These
observations and our clinical experience suggest that (2R,6R;2S,6S)-HNK or one of its
enantiomers may have a therapeutic role in the treatment of refractory chronic migraine patients
with a 5-day infusion of (R,S)-ketamine. However, the distribution of (R,S)-ketamine
metabolites in these patients has not yet been studied.
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Retrospective evidence suggests that a 5-day infusion of (R,S)-ketamine may be
beneficial in the treatment of refractory chronic migraine, but prospective evidence is lacking.
Data on (R,S)-ketamine’s metabolism and distribution in such patients and how they may relate
to individual response to treatment are not known. We therefore performed a prospective,
observational pilot study comparing the analgesic benefit of a 5-day (R,S)-ketamine infusion to
retrospectively collected standard treatment data with lidocaine infusion determined in the same
patients during two separate treatment admissions. Since the enantiomeric composition of
(2R,6R;2S,6S)-HNK during a 5-day continuous infusion of (R,S)-ketamine had not been
previously determined, the secondary endpoint was to characterize the metabolic profile of
(2R,6R)-HNK and (2S,6S)-HNK in patients with refractory chronic migraine and determine if an
association exists between clinical response and metabolite levels.
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Materials and Methods
General Methods and Data Collection
This study was approved by the Institutional Review Board of Thomas Jefferson
University on March 20, 2019 and was carried out in accordance with the Declaration of
Helsinski. All patients provided written informed consent. Patients were identified by headache
physicians or the research coordinator at the time of their office visit after the initial
hospitalization for lidocaine from December 2018 to October 2019 at Methodist Hospital in
Philadelphia, PA. Once the patient was scheduled for a second inpatient hospitalization by the
headache physician, which typically meant the patient had reported an improvement in average
daily pain of either 0 or 1 on the 0-10 numeric rating scale since the initial hospitalization, the
patient was approached for enrollment in the prospective, observational study. Hospitalizations
for ketamine occurred from June 2019 to December 2019 at Thomas Jefferson University
Hospital in Philadelphia, PA. All patient follow-up phone calls took place between 8 and 18 days
of discharge from the hospital. The study was registered on clinicaltrials.gov prior to patient
enrollment (NCT03896256) and was conducted according to recommendations from the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.9
Patients age 18 years and older with a diagnosis of chronic migraine10 who met refractory criteria
for class IV2 were eligible. Patients with a contraindication to ketamine, including schizophrenia,
active psychosis, pregnancy, poorly controlled cardiovascular disease, cirrhosis,3 or previous
treatment with intravenous (IV) ketamine, were excluded. Neither patients nor assessors were
blinded as this was an open-label, prospective, observational study.
Historical data from the first hospitalization of patients receiving lidocaine and other IV
agents were collected for all patients from manual queries of the electronic medical record. In
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addition, data during and after hospitalization for ketamine were prospectively collected by a
research nurse. Data collected included: demographics, pain levels (baseline, throughout both
hospitalizations, and at first post-discharge office visit), medications, and times of blood
samples. Primary outcome data (pain ratings) were obtained from the electronic medical record
(Epic) for lidocaine hospitalizations and from prospective patient assessment for ketamine
hospitalizations. Pain ratings were recorded using a 0-10 verbal numerical rating scale where
0=no pain and 10=worst pain imaginable.

Lidocaine Treatment Protocol and Admission
Patients with refractory chronic migraine were admitted for 5 days to Methodist Hospital
for lidocaine infusion. Methodist is a Jefferson-affiliated community hospital approximately 5
miles away from the main hospital and is the location of the Jefferson Headache Center Inpatient
Unit. A baseline pain rating was obtained and a lidocaine infusion at 1 mg/min was started on
day 1 or 2. The lidocaine infusion was titrated daily based on reported pain levels, the presence
of adverse effects, and daily lidocaine plasma levels. Patients were questioned daily about the
presence of adverse effects. The target plasma level was not to exceed 5 mcg/mL and the
lidocaine infusion rate was not to exceed 4 mg/min. Preventive migraine medications taken at
home were continued during the hospitalization. Additional IV medications were used as needed.

Ketamine Treatment Protocol and Admission
Patients were admitted for 5 days to Thomas Jefferson University Hospital for
management of refractory chronic migraine with a continuous ketamine infusion. Baseline liver
function tests were obtained as well as baseline metabolite levels prior to starting the infusion.
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(R,S)-ketamine (Ketalar) was started at 10 mg/h and was increased every 4-6 hours in increments
of 5-10 mg/h up to the point of intolerable adverse effects or 1 mg/kg/h, whichever came first.
Patients were questioned about the presence of adverse effects (hallucinations, nightmares,
nausea, and vomiting) at the times of pain assessments and blood draws. Ketamine metabolite
blood draws occurred at baseline, 24, 72, and approximately 120 hours from beginning of
infusion. Preventive migraine medications taken at home were continued during the
hospitalization.

Blood Sample Collection and Analysis
Ketamine metabolites have been studied previously in a patient with complex regional
pain syndrome receiving a 5-day continuous ketamine infusion. Steady state plasma metabolites
were analyzed on day 3 while the patient was reporting maximal pain relief and
hydroxynorketamine was found to be the predominant circulating metabolite.8 We therefore
designed this study to measure plasma samples at baseline, 24 hours, 72 hours, and at the end of
infusion, which was approximately 120 hours. Samples were analyzed for the following
compounds: (R,S)-ketamine, (R)- and (S)-norketamine, (R,S)-dehydronorketamine (DHNK), and
(2R,6R)-HNK and (2S,6S)-HNK. Pain ratings were assessed at the times of sample collection
and the rate of the ketamine infusion was also recorded.
Venous blood was collected in 5-mL ethylenediamine tetraacetic acid tubes by a research
team member and immediately centrifuged and separated into plasma and blood components.
They were then transported to a monitored freezer and stored at -70°C until they were shipped
for analysis. Samples were shipped in temperature-controlled containers to an external laboratory
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for analysis. A total of 4 samples per patient were collected, stored, and shipped. Samples were
shipped according to established protocols to ensure maintenance of sample storage temperature.
Plasma concentrations of ketamine and its metabolites were determined using a
previously described achiral method on a Shimadzu Prominence high-performance liquid
chromatography system and a triple quadrupole mass spectrometer, model API 4000 system
from Applied Biosystems/MDS Sciex equipped with Turbo Ion Spray® (TIS).8, 11 Resolution of
(2R,6R)-HNK, (2S,6S)-HNK, (R)-norketamine, and (S)-norketamine was achieved via a
previously described method with slight modifications.12 Briefly, separation of the metabolites
was accomplished on a Lux® Amylose-2, LC Column (150 x 4.6 mm, 3um, Phenomenex,
Torrance, CA) at 40oC, with mobile phase A consisting of ammonium acetate (5mM, pH 9) and
mobile phase B consisting of isopropanol and acetonitrile (4:1). Data were acquired using a
Nexera XR HPLC (Shimadzu, Kyoto, Japan) coupled with a QTRAP 5500 (SCIEX) and
analyzed with Analyst 1.6 (SCIEX).

Sample Size Calculation and Statistical Analysis
Prior work by our group has shown that a 5-day ketamine infusion is associated with a
reduction in short-term pain of approximately 55%.4 Conservatively assuming a reduction in
pain by 50%, the sample size was calculated using a paired t-test assuming a mean difference of
4 points with standard deviation (SD) of 2.5 in the 0-11 numerical rating scale for pain from preto post-treatment. Using those assumptions with alpha set at 0.05 and 87.5% power, a sample
size of 6 pairs would detect a significant difference in pain between ketamine and standard
treatment with lidocaine.
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Comparisons of pain ratings between hospitalizations were performed using the Kruskal
Wallis test. Comparisons of changes in pain over time between and within each hospitalization
were performed using one and two-way analysis of variance with repeated measures with a
Bonferroni correction for multiple comparisons. Plasma concentrations of ketamine,
norketamine, HNK, and DHNK and their enantiomers were analyzed using one-way analysis of
variance with repeated measures with Bonferroni correction for multiple comparisons.
Correlations between the mean daily pain ratings and ketamine metabolite concentrations were
analyzed using the Pearson correlation coefficient. Continuous data are reported as means ± SD.
All statistical analyses were performed using Systat, version 13 (San Jose, CA). A p-value of
0.05 was considered statistically significant. All 6 patients had complete pain data for the
ketamine and lidocaine hospitalizations.
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Results
Demographics and Pain Outcomes
A total of 7 patients who had completed a treatment course of lidocaine during a previous
hospitalization were screened for eligibility over a 6-month period. All 7 patients signed written
informed consent and were enrolled in the study and underwent all study procedures and
Supplemental Figure S1 shows the patient flow diagram. One of the patients was later
determined to have a diagnosis other than chronic migraine and was excluded from analysis
leaving 6 patients for analysis. The patients ranged in age from 20-55 years and half were
female. Two patients had a diagnosis of depression. Five out of the 6 patients received
dihydroergotamine during the initial hospitalization in addition to the lidocaine infusion, which
is the typical protocol. All 6 patients had complete data for all pain outcomes, including baseline,
end of treatment, and post-discharge pain ratings. Patients reported a mean baseline pain rating
(0-10 numeric rating scale) of 7.5 ± 2.2 prior to initial admission for lidocaine, which decreased
to 4.7 ± 2.8 by the end of the hospitalization (p≤0.05); when comparing baseline pain to pain at
the first post-discharge office visit, there was no difference (7.5 ± 2.2 vs. 7.0 ± 1.4, p>0.05).
This visit occurred at a mean time of 28 ± 8 days after treatment. The mean lidocaine infusion
rate on day 1 was 1.6 ± 0.8 mg/min and 2.5 ± 0.7 mg/min on day 4.
At the time of the hospitalization for ketamine, no patients were taking opioids and all 6
patients had Migraine Disability Assessment (MIDAS) scores of grade 4, indicating severe
disability.13 All 6 patients had complete pain data, including baseline, end of treatment, and postdischarge pain ratings. Prior to ketamine treatment the mean baseline pain rating was 7.4 ± 1.4,
which decreased to 3.7 ± 2.3 by the end of the hospitalization (p≤0.05). There was no statistical
difference between baseline pain and pain at the first post-discharge office visit (7.4 ± 1.4 vs. 7.2

12
± 1.7, p>0.05), which occurred at a mean time of 41 ± 7 days after treatment. Ketamine
infusions were started at 10 mg/h for all 6 patients and the mean infusion rate by the end of day 2
was 46.7 ± 9.8 mg/h. The mean maximum infusion rate achieved during admission was 72.5 ±
10.4 mg/h for all patients and occurred on day 5.
When comparing the primary outcome between the two treatments, there was a
statistically significant difference. Patients experienced a statistically greater decrease in pain
rating (0-10 numeric rating scale) after ketamine than lidocaine: -3.7 with ketamine versus -2.8
with lidocaine (p≤0.05). The pain trajectory for patients during both treatment admissions is
shown in Figure 1.

Adverse Effects and Additional Medications
Four of the 6 patients experienced some adverse effects attributed to lidocaine. One
patient experienced four episodes of bradycardia/junctional heart rhythm and nausea; the second
experienced hallucinations and blurry vision; the third experienced nausea and blurry vision; and
the fourth experienced insomnia. All were transient in nature.
All 6 patients experienced some AEs during treatment with ketamine. These included
hallucinations, nightmares, vivid dreams, blurry vision, and nausea/vomiting (see Table 1). None
of the AEs required complete discontinuation of ketamine and all patients completed the full 5day treatment course. None of the patients required discontinuation of either lidocaine or
ketamine infusion for hemodynamic reasons.

Additional medications given to patients during the second treatment admission for
ketamine are shown in Supplemental Table T1. A literature review was conducted to determine
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if metabolic interactions between ketamine and the co-administered drugs had been reported. No
such reports were identified.

Metabolite Analyses
All 6 patients had complete ketamine metabolite and concurrent medication data for
analysis. The circulating plasma concentrations of (R,S)-ketamine increased throughout the 5day treatment and were greatest at the end of the infusion on day 5. Concentrations of (R,S)norketamine and (R,S)-DHNK remained fairly stable from 24 h until the end of infusion, while
hydroxynorketamine levels peaked at 72 h (Table 2, Figure 2). Pearson correlations between
mean daily pain ratings and mean plasma concentrations of (R,S)-ketamine and its metabolites
were as follows: (R,S)-ketamine [R= -0.82, p>0.05]; (R,S)-norketamine [R= -0.53, p>0.05];
(2R,6R,2S,6S)-HNK [R= -0.89, p>0.05)]; (R)-norketamine [R= -0.55, p>0.05]; (S)-norketamine
[R= -0.48, p>0.05]; (2R,6R)-HNK [R= -0.93, p>0.05]; (2S,6S)-HNK [R= -0.79, p>0.05]; and
(R,S)-DHNK [R= -0.95, p>0.05].
The mean concentrations of (R,S)-ketamine, (R)-norketamine, (S)-norketamine, (2R,6R)HNK, (2S,6S)-HNK, and (R,S)-DHNK all increased from baseline to 24 h (Table 2, Figure 2).
The mean concentrations of (R)-norketamine were greater than those of (S)-norketamine at 24 h,
72 h, and the end of infusion (Table 2, Figure 3; p≤0.05). Similarly, the mean concentrations of
(2R,6R)-HNK were greater than those of (2S,6S)-HNK at 72 h and the end of infusion (Table 2,
Figure 4; p≤0.05). The ratio of (2R,6R)-HNK to (2S,6S)-HNK increased from 24 h to the end of
infusion (Table 3; p≤0.05) while the ratio of (R)-norketamine to (S)-norketamine did not,
indicating stereoselective formation of the (2R,6R) enantiomer preferentially over the (2S,6S)
enantiomer or perhaps stereoselective renal clearance of (2S,6S)-HNK.
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Discussion
In this pilot study we have shown that both (R,S)-ketamine and lidocaine infusions have
the potential to reduce short-term pain in patients with refractory chronic migraine. The
reduction in pain associated with (R,S)-ketamine was statistically greater than that with
lidocaine, but this difference has unclear clinical significance given that the minimum clinically
significant change in numeric rating scale pain has been reported as 2 on the 0-10 scale.14 In
addition, the time course of pain relief differed between the infusions in that pain ratings did not
decrease until the end of the lidocaine treatment, while pain relief began to occur on day 3 during
ketamine treatment and remained greater than that obtained from lidocaine until the end of
hospitalization. By the time patients were seen 6 weeks after both treatments their pain level had
returned to baseline. This reflects the clinical challenge of this refractory population. While longterm relief of pain and disability is the goal of both patients and physicians, short-term
improvement is not insignificant for patients with nearly constant symptoms. While both
infusions were associated with AEs, both were tolerated by all patients and no serious AEs
occurred. The clinical improvement demonstrated in this study was consistent with previous
retrospective studies of refractory chronic migraine patients who received lidocaine15 and (R,S)ketamine,4 although the patients in this study reported lower pain ratings for a greater period of
time with ketamine than lidocaine.
Patients with refractory chronic migraine often have disabling pain and those in classes 3
or 4 have failed a minimum of 3 classes of medication2 but often have failed dozens or more in
our clinical experience. The patients in this pilot study all met the criteria for MIDAS grade 4,
indicating a severe level of disability, and 5 of the 6 patients had scores of at least 140, indicating
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nearly constant pain. While clinical trials of patients with episodic migraine or even chronic
migraine typically have clear inclusion and exclusion criteria, the inconsistency in how
intractable or refractory headache is defined makes the inclusion of such patients in clinical trials
difficult.2 Non-traditional treatments that have not been well studied, such as the IV infusions
used in this study, are sometimes the only available options for these patients. Generating the
necessary evidence to support such treatments can be complicated by inconsistent definitions and
endpoints created for less refractory populations. Nevertheless, we have shown that both
infusions can potentially improve short-term pain in the most challenging headache population
and further prospective study is warranted.
(R,S)-ketamine is a chiral phencyclidine derivative that was initially developed as an
anesthetic agent.16 Initial studies demonstrated that (R,S)-ketamine was extensively and
stereoselectively metabolized, that only the (R,S)-norketamine metabolite produced anesthesia in
the rat, and that (2R,6R;2S,6S)-HNK was inactive in this model.17 Thus, pharmacokinetic and
pharmacodynamic studies following acute or sub-chronic (R,S)-ketamine administration
concentrated on (R,S)-ketamine and (R,S)-norketamine or the separate enantiomers. The initial
study of the enantioselective metabolism and distribution of (R,S)-ketamine during a 5-day
infusion was conducted in patients with CRPS but was limited to the examination of (R)ketamine, (S)-ketamine, (R)-norketamine and (S)-norketamine.18 The results of the study
demonstrated that while the plasma concentrations of (R)-ketamine were slightly greater than
(S)-ketamine, the (R)-norketamine concentrations were significantly higher than (S)-norketamine
concentrations.18 While we did not determine the separate concentrations of (R)-ketamine and
(S)-ketamine in the current study, the relative concentrations of (R)-norketamine and (S)norketamine were consistent with the earlier study.
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In the CRPS study, 10 of 16 patients reported a significant reduction (30%) in
individual pain ratings relative to baseline ratings.19 Similar to the data in the current study, the
mean pain ratings decreased over the length of the infusion. A pharmacodynamic analysis
comparing plasma concentrations of the target compounds with the probability of achieving pain
relief indicated that the antinociceptive activity produced by the continuous administration of
(R,S)-ketamine could not be explained by the plasma concentrations of (R)-ketamine, (S)ketamine, (R)-norketamine, or (S)-norketamine. The results suggested that other metabolites may
play a role in the observed therapeutic effects. This led to the reanalysis of a plasma sample from
a complex regional pain syndrome patient classified as a responder using a method able to
quantify all of the major (R,S)-ketamine metabolites.8 The data indicated that (2R,6R;2S,6S)hydroxynorketamine was a major circulating metabolite and that the plasma concentration of this
metabolite was far greater than (R,S)-norketamine.
The current study is the first to re-examine the effect of a continuous 5-day infusion on
the metabolism and distribution of (R,S)-ketamine. In this study, (2R,6R;2S,6S)-HNK was the
predominant circulating compound followed by (R,S)-ketamine, (R,S)-norketamine, and (R,S)DHNK. (R,S)-DHNK is rapidly cleared by renal excretion8,10 and its in vivo pharmacological
activity has not been established. Since urine samples were not collected in the current study, our
analysis was concentrated on the enantiomers of (2R,6R;2S,6S)-HNK.
In the current study, the average plasma concentration of (2R,6R;2S,6S)-HNK peaked at
72 h and it significantly exceeded the concentrations of both (R,S)-ketamine (p<0.05) and (R,S)norketamine (p<0.05). The plasma concentrations of (R,S)-ketamine slowly increased throughout
the infusion in 5 of the 6 patients while (R,S)-norketamine plasma concentrations peaked at 24 or
48 hours followed by a rapid decline. No statistically significant correlation was found between
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(R,S)-ketamine, (R,S)-norketamine, or (2R,6R;2S,6S)-HNK plasma concentrations and mean
daily pain ratings, which is not surprising considering our limited sample size. However, there
were clear non-significant correlations noted between (R,S)-ketamine concentrations and pain, R
= -0.822 (p>0.05) and (2R,6R;2S,6S)-HNK concentrations and pain, R = -0.887 (p>0.05). Since
previous studies had established that (2R,6R)-HNK has analgesic properties,7 the plasma
samples were reanalyzed using an enantioselective chromatographic method to establish the
relative concentrations of (2R,6R)-HNK and (2S,6S)-HNK as well as their immediate precursors
(R)-norketamine and (S)-norketamine. The results indicate that the average plasma concentration
of (2R,6R)-HNK exceeded (2S,6S)-HNK at 24 h and that this difference reached significance at
the 72 h (p<0.05) and Day 5 (p<0.05) sampling times. Indeed, (2R,6R)-HNK plasma
concentrations surpassed (R,S)-ketamine concentrations at 72 h in 5 of the 6 patients and in 4 of
the 6 patients on Day 5.
The data indicate that the ratio of (2R,6R)-HNK:(2S,6S)-HNK increased over the course
of the infusion from 1.9  0.7 at 24 h to 2.9  0.5 on Day 5. Our data identifying a ~2-fold
difference in the circulating concentrations of (2R,6R)-HNK relative to (2S,6S)-HNK 24-h postinfusion are consistent with previous findings. In a recent study, 230 min after the administration
of a single infusion of (R,S)-ketamine, (2R,6R)-HNK was present in greater concentrations than
(2S,6S)-HNK11 and, in a separate single-subject study, (2R,6R)-HNK had a larger systemic
exposure (~1.5 times) than (2S,6S)-HNK.20
The significant increases in these ratios observed at 72 h and at the end of the infusion
suggest that there was a stereoselective induction of the metabolic transformation from (R,S)norketamine to the corresponding HNK metabolites, which favors the production of (2R,6R)HNK, or could indicate stereoselective renal clearance of (2S,6S)-HNK. Previous studies have
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identified CYP2A6 as the primary enzyme involved in the transformation of (R,S)-norketamine
to (2R,6R;2S,6S)-HNK and determined that this process is stereoselective favoring the
conversion of (R)-norketamine to (2R,6R)-HNK,5 and cell-based studies have demonstrated that
(R,S)-ketamine, (2R,6R)-HNK, and (2S,6S)-HNK induce CYP2A6 expression and function.22
The latter study also demonstrated that the same compounds induce CYP2B6 expression and
function.22 Since CYP2B6 mediates the conversion of (R,S)-norketamine to (R,S)-DHNK, one
would expect to see this reflected in a change in the (R)-norketamine:(S)-norketamine ratio over
time. However, this was not observed, suggesting that CYP2B6 induction did not occur, or that
any changes were obscured by the rapid renal clearance of DHNK. Additional experiments,
including the analysis of urine samples, are required in larger sample cohort to determine
whether induction, clearance, or both are responsible for the significant increase of (2R,6R)HNK over (2S,6S)-hHNK during a continuous infusion of (R,S)-ketamine.
The results of this study demonstrate that (2R,6R)-HNK was the major circulating
compound at 72 h and at the end of the infusion and that these time points coincide with the
optimum pain relief. While no correlation was found between overall improvement in pain and
(2R,6R)-HNK, these preliminary findings should be further explored in a larger cohort to
determine whether (2R,6R)-HNK could be a viable therapeutic agent for chronic pain conditions
such as migraine or complex regional pain syndrome. Current evidence of the benefits have been
from preclinical studies in animals using pain models7 and in refractory depression.6, 21 While the
data are inconclusive, the indication that there has been an induction of CYP2A6 suggest a
potential mechanism for the compound’s antinociceptive activity observed in animal pain
models. Recent cell-based studies have demonstrated that (R,S)-ketamine, (2R,6R)-HNK, and
(2S,6S)-HNK bind to the estrogen receptor  (ER) and in coordination with estrogens enhance
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the ER-induced transcription of CYP2A6 and CYP2B6 as well as the increased expression of
ER.22 Thus, the continuous infusion of (R,S)-ketamine and the buildup of (2R,6R)-HNK may
invoke an ER-related mechanism not observed after a single rapid infusion of (R,S)-ketamine,
(2R,6R)-HNK, or (2S,6S)-HNK. This possibility has not been demonstrated in vivo and will be
explored in future clinical studies.
Our results are generalizable to other clinical settings where 5-day ketamine infusions are
used. However, the clinical significance of (2R,6R;2S,6S)-HNK being the predominant
metabolite throughout much of the infusion is not yet known and our results could be used as the
basis to study the role of these metabolites in pain, particularly during prolonged infusions.
Our study has several limitations. In addition to the small sample size, retrospectively
collected pain ratings from the lidocaine hospitalizations were not always assessed at consistent
intervals and could be subject to influence based on the time of day and medications given just
prior to assessment. Follow-up pain ratings were in some cases obtained via telephone call
several months after treatment and could be subject to recall bias. Our results may not be
generalizable to other practices where lower (R,S)-ketamine or lidocaine doses are used or
different adjunctive medications are used. Our results also may not apply to less refractory
patients. Lastly, our study was open label and we were unable to control for the additional
medications that patients were given during admission, such as dihydroergotamine and ketorolac.
It is unknown how these or other medications might have influenced pain. Future studies
including pre-treatment and post-treatment metabolic phenotyping for CYP2B6 and CYP2A6
activity and urinary excretion are necessary to help elucidate whether those enzymes play a role
in the pharmacological mechanisms responsible for the observed effects.
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Conclusions
Patients with refractory chronic migraine have continuous pain and substantial disability.
We have shown that both lidocaine and (R,S)-ketamine infusions hold potential to reduce shortterm pain and “break the cycle” of constant symptoms, with a more pronounced reduction in pain
score with (R,S)-ketamine treatment. In this study, no statistically significant correlation was
found between pain scores and circulating levels of (R,S)-ketamine or its metabolites.
Circulating concentrations of (2R,6R)-HNK, however, were at their highest between Days 3 and
5, the period of time when pain was at its lowest, suggesting the possibility that this molecule
could hold promise as an analgesic that lacks (R,S)-ketamine’s psychomimetic adverse effects,
although this should be interpreted with caution given the small sample size. Our results suggest
that future studies should be undertaken to explore this further. Preliminary data from this study
suggest that (R,S)-ketamine may induce its metabolism throughout the treatment period in a
stereoselective fashion that favored formation of the (2R,6R)-HNK isomer.
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